{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:28:41Z","timestamp":1760711321098},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,20]]},"DOI":"10.7759\/cureus.54564","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T20:03:35Z","timestamp":1708459415000},"source":"Crossref","is-referenced-by-count":2,"title":["SARS-CoV-2 Persistence in Immunocompromised Patients Requiring Treatment With Convalescent Plasma: A Case Report"],"prefix":"10.7759","author":[{"given":"Gabrielle","family":"Librizzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viraj","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audun J","family":"Lier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa863","article-title":"COVID-19 in immunocompromised hosts: what we know so far","author":"Fung M","year":"2020","unstructured":"Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2020, ciaa863. 10.1093\/cid\/ciaa863","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04924-6","article-title":"Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies","volume":"101","author":"Magyari F","year":"2022","unstructured":"Magyari F, Pincz\u00e9s LI, P\u00e1yer E, et al.. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies. Ann Hematol. 2022, 101:2337-45. 10.1007\/s00277-022-04924-6","journal-title":"Ann Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac382","article-title":"Extended Remdesivir infusion for persistent coronavirus disease 2019 infection","volume":"9","author":"Martinez MA","year":"2022","unstructured":"Martinez MA, Chen TY, Choi H, et al.. Extended Remdesivir infusion for persistent coronavirus disease 2019 infection. Open Forum Infect Dis. 2022, 9:ofac382. 10.1093\/ofid\/ofac382","journal-title":"Open Forum Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29104-y","article-title":"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report","volume":"13","author":"Gandhi S","year":"2022","unstructured":"Gandhi S, Klein J, Robertson AJ, et al.. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat Commun. 2022, 13:1547. 10.1038\/s41467-022-29104-y","journal-title":"Nat Commun"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23699","article-title":"Successful treatment of SARS-CoV-2 in an immunocompromised patient with persistent infection for 245 days: a case report","volume":"10","author":"Overbeck V","year":"2024","unstructured":"Overbeck V, Taylor BP, Turcinovic J, et al.. Successful treatment of SARS-CoV-2 in an immunocompromised patient with persistent infection for 245 days: a case report. Heliyon. 2024, 10:e23699. 10.1016\/j.heliyon.2023.e23699","journal-title":"Heliyon"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa619","article-title":"To interpret the SARS-COV-2 test, consider the cycle threshold value","volume":"71","author":"Tom MR","year":"2020","unstructured":"Tom MR, Mina MJ. To interpret the SARS-COV-2 test, consider the cycle threshold value. Clin Infect Dis. 2020, 71:2252-4. 10.1093\/cid\/ciaa619","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.50647","article-title":"COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis","volume":"6","author":"Senefeld JW","year":"2023","unstructured":"Senefeld JW, Franchini M, Mengoli C, et al.. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis. JAMA Netw Open. 2023, 6:e2250647. 10.1001\/jamanetworkopen.2022.50647","journal-title":"JAMA Netw Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/225485-sars-cov-2-persistence-in-immunocompromised-patients-requiring-treatment-with-convalescent-plasma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T20:03:39Z","timestamp":1708459419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/225485-sars-cov-2-persistence-in-immunocompromised-patients-requiring-treatment-with-convalescent-plasma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.54564","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,20]]}}}